Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · IMPACT BIOMEDICAL INC. (IBO)

Impact Biomedical announces 1-for-12.62 reverse stock split effective September 23

Neutral Impact 3 of 5 shareholder Written later

Impact Biomedical Inc. (NYSE American: IBO) said its 1-for-12.62 reverse stock split will take effect at 12:01 a.m. Eastern Time on September 23, 2026, reducing outstanding common shares from about 107.8 million to about 8.5 million. The company said the split is connected to its proposed merger with Zoar Limited and to regaining compliance with NYSE American listing requirements, but it gave no assurance that either goal will be met. The filing also corrects an earlier press release that misstated the merger exchange ratio.

Key points

  • Reverse split ratio of 1-for-12.62 takes effect 12:01 a.m. Eastern Time on September 23, 2026; ticker remains IBO under a new CUSIP.
  • Shares outstanding expected to fall from 107,821,231 to 8,543,679, subject to rounding; fractional shares are rounded up to the next whole share.
  • Merger terms: one Zoar Limited share for each Impact share held immediately before the merger, after giving effect to the split.
  • A corrected press release replaces the September 11, 2026 release, which incorrectly stated a one-for-four exchange ratio.

The filing

CompanyIMPACT BIOMEDICAL INC. (IBO)
Form8-K, current report
Filed with the SECSep 14, 2026, 7:43 PM ET
Accession number0001493152-26-042635

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 14, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.